Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 6/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14908532 | 0.92 | SIGMAR1 (0.41) | SIGMAR1TIPARPCHRNB2CHRNA4FAAH | |
| SCHEMBL13976198 | 0.79 | SIGMAR1 (0.36) | SIGMAR1TIPARPCHRNB2CHRNA4PDE3B | |
| SCHEMBL13966518 | 0.79 | SIGMAR1 (0.36) | SIGMAR1TIPARPCHRNB2CHRNA4PDE3B | |
| SCHEMBL256354 | 0.75 | SIGMAR1 (0.46) | SIGMAR1TIPARPCHRNB2CHRNA4NAMPT | |
| SCHEMBL14769042 | 0.73 | MAOA (0.46) | — | |
| SCHEMBL13966519 | 0.72 | SIGMAR1 (0.36) | SIGMAR1TIPARPCHRNB2CHRNA4NAMPT | |
| SCHEMBL15462822 | 0.72 | SIGMAR1 (0.36) | SIGMAR1TIPARPCHRNB2CHRNA4NAMPT | |
| SCHEMBL9965909 | 0.71 | MAOA (0.55) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL16298139 | 0.70 | SIGMAR1 (0.50) | SIGMAR1TIPARPCHRNB2CHRNA4PDE3B | |
| SCHEMBL147460 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| US-9504728-B2 | Dosage form | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-11-29 | — | — | US | disclosed |
| US-9139613-B2 | Macrocyclic compounds and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-22 | — | — | US | disclosed |
| US-9119853-B2 | Sanglifehrin based compounds | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-09-01 | — | — | US | disclosed |
| EP-2533784-B1 | SANGLIFEHRIN BASED COMPOUNDS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-04-22 | — | — | EP | disclosed |
| US-20140234414-A1 | Novel Dosage Form | Abliva Ab (SE) | 2014-08-21 | — | — | US | disclosed |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-02-06 | — | — | US | disclosed |
| WO-2013061052-A1 | NOVEL DOSAGE FORM | BIOTICA TECHNOLOGY LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234414-A1 | Novel Dosage Form | SI, RAB10, SAMM50 | SIGMAR1 2125/4885TIPARP 1256/4885CHRNB2 4740/4885 |
| US-20140038885-A1 | Macrocyclic Compounds and Methods for Their Production | HAVCR2, RPL35, CD4 | SIGMAR1 3849/4885TIPARP 1683/4885CHRNB2 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.